Table 4.
Complications and treatments of all 18 patients infected with SARS‐CoV‐2
| No. (%) | |
|---|---|
| Complications | |
| ARDSa | 3 (17%) |
| Liver injurya | 3 (17%) |
| Treatment | |
| Oxygen therapy | |
| Nasal cannula | 10 (56%) |
| Noninvasive ventilation or high‐flow nasal cannulab | 3 (17%) |
| Mechanical ventilation (noninvasive)b | 3 (17%) |
| Antiviral treatment | |
| Lopinavir/ritonavir, interferon‐α2b | 18 (100%) |
| Oseltamivir | 5 (28%) |
| Ribavirin | 6 (33%) |
| Antibacterial treatment, moxifloxacin | 11 (61%) |
| Methylprednisoloneb | 3 (17%) |
| Immunoregulation therapy, thymalfasin, immunoglobulinb | 3 (17%) |
| Convalescent plasma | 4 (22%) |
| Traditional Chinese medicine | 18 (100%) |
Abbreviations: ARDS, acute respiratory distress syndrome; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
a
Complications occurred in three severe patients.
b
These therapies were only used for three severe patients.